Group 1 - The core point of the article is that Zhendong Pharmaceutical held its 10th meeting of the 6th Board of Directors on December 18, 2025, to discuss the election of members for the Compensation and Assessment Committee [1] - For the first half of 2025, Zhendong Pharmaceutical's revenue composition includes: 110.27% from pharmaceutical production and sales, 31.67% from medicinal herb planting, 3.38% from technical services, and -45.32% from inter-segment eliminations [1] - As of the report date, Zhendong Pharmaceutical has a market capitalization of 6 billion yuan [1]

Group 1 - The core point of the article is that Zhendong Pharmaceutical announced a board meeting to discuss providing guarantees for its wholly-owned subsidiary [1] - For the first half of 2025, Zhendong Pharmaceutical's revenue composition includes: pharmaceutical production and sales accounting for 110.27%, medicinal herb planting at 31.67%, and technical services at 3.38%, with inter-segment eliminations at -45.32% [1] - As of the report, Zhendong Pharmaceutical has a market capitalization of 6.9 billion yuan [1]

Group 1 - The company, Zhendong Pharmaceutical, announced a share buyback of approximately 13.02 million shares, representing 1.29% of its total share capital, with a total expenditure of about 52.03 million RMB [1] - The highest and lowest prices for the share buyback were 10.06 RMB and 3.51 RMB per share, respectively [1] - As of the report date, the market capitalization of Zhendong Pharmaceutical is 8.6 billion RMB [1] Group 2 - For the first half of 2025, the revenue composition of Zhendong Pharmaceutical is as follows: pharmaceutical production and sales accounted for 110.27%, herbal planting industry for 31.67%, and technical services for 3.38%, with inter-segment eliminations at -45.32% [1]